Multi-Compartmental Vaccine Delivery System for Enhanced Immune Response to gp100 Peptide Antigen in Melanoma Immunotherapy
- 421 Downloads
To develop a multi-compartmental vaccine delivery system for safe and efficient delivery of the gp100 peptide antigen in melanoma immunotherapy.
Water-in-oil-in-water (W/O/W) multiple emulsion-based multi-compartmental vaccine delivery system containing the gp100 peptide was prepared by a two-step emulsification method. In vivo prophylactic and active immunization effectiveness of the novel squalane oil-containing gp100 vaccine was evaluated in the murine B16 melanoma model and compared with that of an incomplete Freund’s adjuvant (IFA)-based vaccine.
Morphological evaluation of the W/O/W multiple emulsions showed that the oil-droplets were homogenously dispersed with the gp100 peptide encapsulated in an inner aqueous phase. Immunization with the gp100 peptide delivered in the W/O/W multiple emulsions-based vaccine resulted in increased protection against tumor challenge compared to IFA-based vaccine (p < 0.05, n = 8) signifying induction of enhanced anti-tumor immunity. In addition, serum Th1 cytokine levels and immuno-histochemistry of excised tumor tissues indicated activation and local infiltration of antigen specific cytotoxic T-lymphocytes into and/or surrounding the tumor mass. Moreover, the newly developed vaccine formulation did not induce any overt systemic toxicity.
Novel W/O/W multiple emulsions-based vaccine efficiently delivers the gp100 peptide antigen to induce cell-mediated anti-tumor immunity and offers an alternate, safe vaccine delivery system.
KEY WORDSanti-tumor immunity cancer vaccine gp100 peptide antigen melanoma W/O/W multiple emulsions
incomplete Freund’s adjuvant
squalane oil multiple emulsions
- 4.Bozkir A, Saka OM. Multiple emulsions: delivery system for antigens. Multiple emulsions: John Wiley & Sons, Inc; 2007. 293–306.Google Scholar
- 5.Silva-Cunha AGJ, Seiller M. Multiple emulsions pharmaceutical potentiality. In: M GJS, editor. Multiple emulsions: structure, properties and applications. de Sante, France: Éd. de Santé; 1999. 279–312.Google Scholar
- 8.Pass RF, Duliegè AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Pediatr Infect Dis. 1999;180(4):970–5.Google Scholar
- 9.Nitayaphan S, Khamboonruang C, Sirisophana N, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine. 2000;18(15):1448–55.PubMedCrossRefGoogle Scholar
- 10.Rosenthal ML. Squalane: the natural moisturizer. In: Schlossman ML, editor. Chemistry and manufacture of cosmetics 3 ed; 2002. 869–875.Google Scholar
- 26.Schriber H. Tumor immunology. In: Paul WE, editor. Fundamental immunology. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 1557–92.Google Scholar
- 27.Kenneth M, Murphy PT, Walport M. Immunobiology. 5th ed. New York: Garland Science; 2001.Google Scholar
- 40.Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J Immunol. 2004;172(2):776–86.PubMedGoogle Scholar